Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular ...

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.

On July 17, 2025, a panel of experts convened by the FDA voiced growing consensus that the boxed warning on menopausal hormone therapies, particularly low-dose vaginal estrogen, is an outdated or ...

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on the newly FDA-approved Neuspera integrated ...

"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD. On July 17, 2025, a panel of experts convened by the FDA outlined the growing ...

An expert summarizes that TARA-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in ...

According to Song, novel aspiration technologies are reshaping not only care delivery, but also long-term treatment outcomes. The emergence of new aspiration devices for stone disease has been a ...

Bladder cancer is a challenging and recurrent disease that significantly impacts both those experiencing it and those providing care. Its management demands ongoing surveillance and frequent ...

Metastasis-directed radiotherapy without systemic therapy (MRWS) demonstrated promising efficacy with manageable safety in patients with oligometastatic clear cell renal cell carcinoma (ccRCC), ...

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.